A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer

Cancer Investigation
Gregory P KalemkerianM J Kraut

Abstract

Despite the recent development of new chemotherapeutic agents with activity in small cell lung cancer (SCLC), the long-term prognosis of patients with extensive-stage disease remains poor and has not improved in the past 20 years. The present study was designed to evaluate the activity and toxicity of weekly, alternating-regimen chemotherapy in patients with extensive-stage SCLC. Patients with previously untreated extensive-stage SCLC and performance status 0-2 were treated with cyclophosphamide 250 mg/m2, etoposide 100 mg/m2, and cisplatin 50 mg/m2 on day 1; vincristine 1 mg/m2 on day 8; and ifosfamide 1.2 gm/m2 on days 8 and 9 with the entire treatment repeated every 14 days. Eighteen patients received chemotherapy for a median of 14 weeks (range, 1-35 weeks). Seventeen patients (94%) required dose delays and 16 patients (89%) required at least one dose reduction due to toxicity. Twelve patients (67%) exhibited an objective response (1 complete response, 11 partial response) with a median duration of response of 18 weeks (range, 8-32 weeks). Median survival was 33 weeks (range, 1-57 weeks) with a 1-year survival rate of 22%. Toxicity was primarily hematologic, including grade 3-4 leukopenia (82% of patients) and anemia (53% o...Continue Reading

References

Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MurrayN Voss
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D W MilesS G Spiro
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C W TaylorR B Livingston
Jun 1, 1995·Chest·W J O'Donnell
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L SouhamiC Trask
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SculierJ Michel
Sep 11, 1998·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·U N LassenP Dombernowsky

❮ Previous
Next ❯

Citations

Nov 7, 2019·The Cochrane Database of Systematic Reviews·Sarah L ColeridgeJo Morrison

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.